YILI CHUANNING BIOTECHNOLOGY CO.,LTD. Business Segments Yili Chuanning Biotechnology Co.,Ltd.
Equities
301301
CNE100005WX0
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.62 CNY | -1.21% |
|
-1.21% | +26.43% |
| Aug. 26 | Yili Chuanning Biotechnology Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 | CI |
| Jul. 11 | Yili Chuanning Biotechnology Gets Nod to Market Ursodeoxycholic Acid | MT |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
: Breakdown by Business Segment
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
Medicine Manufacturing | - | - | 3.05B | 3.57B | 4.51B | |
Unallocated Other | - | - | 177M | 247M | 309M | |
Ursodeoxycholic Acid | 15.72M | 2.94M | - | - | - | |
7-Aminodeacetoxycephalosporanic Acid | - | 115M | - | - | - | |
Deacetyl-7-Aminocephalosporanic Acid | 257M | 211M | - | - | - | |
Penicillin G Potassium Salt | 306M | 403M | - | - | - | |
Erythromycin Thiocyanate | 773M | 1.17B | - | - | - | |
7-Aminocephalosporanic Acid | 635M | 581M | - | - | - | |
6-Aminopenicillanic Acid | 862M | 885M | - | - | - |
Geographical Revenue Distribution History
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
East China | - | - | 668M | 1.26B | 2.17B | |
North China | - | - | 1.13B | 1.15B | 1.25B | |
Export | - | - | 563M | 295M | 575M | |
Northwest | - | - | 229M | 245M | 311M | |
Southwest | - | - | 216M | 250M | 270M | |
Central China | - | - | 305M | 327M | 103M | |
South China | - | - | 54.3M | 154M | 78.73M | |
Northeast | - | - | 65.75M | 134M | 65.83M | |
Southeast | - | - | 14.13K | 94.34K | - | |
China | 3.14B | 3.65B | - | - | - | |
Total Assets | 9.89B | 9.92B | - | - | - | |
Interest Expense | -190M | -174M | - | - | - | |
Income Tax Expense | 20.04M | 47.07M | - | - | - | |
D&A | 456M | 491M | - | - | - | |
CAPEX | -65.44M | -89.19M | - | - | - | |
Net Income | 91.39M | 229M | - | - | - | |
EBT | 110M | 276M | - | - | - | |
Operating Income | 117M | 279M | - | - | - |